Pfizer (PFE 0.77%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

CompanyOverview\|NYSE:PFE] A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. (NYSE: PFE) certainly catches the eye of income- ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Prices of newly launched drugs in the U.S. have more than doubled from 2021 to 2024, driven by rare disease therapies, ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Markets expect ...

Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific antibody from 3Sbio Inc. that recently won ...

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion ...

MOODY'S on Monday downgraded the long-term ratings of top American lenders such as JP Morgan Chase, Bank of America (BofA) and Wells Fargo after pushing the United States out of top triple-A rating ...

The deal comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital Markets ...

The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...